AEMD : Summary for AETHLON MEDICAL INC - Yahoo Finance

U.S. Markets closed

Aethlon Medical, Inc. (AEMD)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.89+0.14 (+3.73%)
At close: 4:00PM EST
People also watch
CTSOAMARADXSBLFSBKYI
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.75
Open3.75
Bid0.00 x
Ask4.99 x 200
Day's Range3.75 - 4.00
52 Week Range3.55 - 9.09
Volume54,865
Avg. Volume22,893
Market Cap30.97M
Beta2.70
PE Ratio (TTM)-4.40
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire14 hours ago

    Aethlon Medical CEO Note: Bill Gates on the Threat of Bioterrorism

    SAN DIEGO, Feb. 24, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. In a chilling address at the Munich Security Conference last Saturday, Bill Gates warned world leaders that a genetically engineered virus could kill more people than nuclear weapons. If you are a shareholder of Aethlon Medical, you may recognize the concerns of Mr. Gates to be eerily similar to our own.

  • PR Newswire3 days ago

    Aethlon Medical Reports Results of Cytomegalovirus, Epstein-Barr and Herpes Simplex Virus Studies

    The objective of the study was to validate the in vitro capture of Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes Simplex virus 1 (HSV1) by the Hemopurifier®. The Company also reported that it conducted a related study to identify the presence of each of these viruses in blood samples obtained from organ transplant patients who were also suffering from sepsis.

  • Zacks Small Cap Research10 days ago

    AEMD: FDA Discussions Regarding U.S. Clearance Pathway

    Aethlon (AEMD) reported financial results for their fiscal third quarter 2017 (ending December 2016) and provided an operational update.  There were no meaningful surprises in the financial results relative to our expectations with the top-line ($0 A vs. $8k E), operating expenses ($1.2M A vs. $1.3M E), net loss ($1.2M A vs. $1.3M E) and EPS (-$0.15 A vs. -$0.16) E) all coming in just about exactly where we had modeled. Relative to the balance sheet, AEMD exited fiscal Q3 with $628k cash and equivalents.  They raised $288k and $578k (net) from the sale of equity (via ATM) and convertible notes, respectively, during the quarter.  Subsequent to quarter-end, AEMD raised an additional $256k (net) via the sale of 64k common shares @ $3.98/share average through their ATM program.  Aethlon raised ~$810k through the ATM program since the beginning of Q2 and there remains ~$11M still available.